Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA

Article Stock Quotes (1) Comments (0)

Pfizer (NYSE: PFE) reports that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

Axitinib, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which are receptors that can influence tumor growth, vascular angiogenesis, and progression of cancer.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Pfizer (PFE) to Split Off Remaining Interest in Zoetis (ZTS)
• Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
• StreetInsider.com Pre-Open Movers 5/22: (ZLC) (SKS) (TOL) Higher; (UAN) (TGT) (SODA) Lower (more...)

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?